Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Casi Pharmaceuticals Inc
(NQ:
CASI
)
5.250
-0.010 (-0.19%)
Streaming Delayed Price
Updated: 3:59 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Casi Pharmaceuticals Inc
< Previous
1
2
3
4
5
Next >
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results
November 15, 2024
Via
ACCESSWIRE
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia
October 24, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 09, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 01, 2024
Via
Benzinga
CASI Stock Earnings: CASI Pharmaceuticals Beats EPS, Misses Revenue for Q2 2024
August 16, 2024
CASI stock results show that CASI Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Recap: CASI Pharmaceuticals Q4 Earnings
March 28, 2024
Via
Benzinga
CASI Pharmaceuticals: Q1 Earnings Insights
May 17, 2023
Via
Benzinga
CASI Pharmaceuticals Earnings Perspective: Return On Capital Employed
May 01, 2023
Via
Benzinga
Earnings Scheduled For November 14, 2024
November 14, 2024
Via
Benzinga
3 Promising Biotech Stocks You Can Pick Up for Less Than $10
July 29, 2024
Healthcare innovations are big business. That said, biotech stocks under $10 may offer a higher ceiling thanks to their low price.
Via
InvestorPlace
Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary
June 30, 2024
Shanghai Henlius Biotech agreed to be a wholly owned subsidiary of Fosun in a $690 million deal that values the company at $1.7 billion. Meanwhile, Suzhou Ascentage Pharma filed to list in the US to...
Via
Talk Markets
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
June 27, 2024
Pre-market stock movers are worth checking out on Thursday as we dig into all of the biggest news moving shares this morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
June 21, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
June 20, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 15, 2024
Via
Benzinga
CASI Stock Earnings: CASI Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
May 14, 2024
CASI stock results show that CASI Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
CASI Stock Earnings: CASI Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023
March 28, 2024
CASI stock results show that CASI Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
12 Health Care Stocks Moving In Friday's Intraday Session
March 08, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
March 07, 2024
Via
Benzinga
CASI Pharmaceuticals Blood Cancer Drug Shows Encouraging Clinical Efficacy In Chinese Patients
March 05, 2024
CASI Pharmaceuticals and BioInvent share promising results for BI-1206 in treating relapsed/refractory indolent Non-Hodgkin's Lymphoma patients in China. Preliminary data reveals clinical efficacy with...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 05, 2024
Via
Benzinga
Week In Review: LianBio To Close Operations; Will Pay $528 Million To Shareholders
February 17, 2024
LianBio, a Princeton-Shanghai biotech, has decided to call it quits. LianBio plans to stop all of its operations by the end of 2024, and it will distribute a $4.80 dividend/share ($528 million) to its...
Via
Talk Markets
12 Health Care Stocks Moving In Thursday's After-Market Session
January 25, 2024
Via
Benzinga
HC Wainwright & Co. Maintains Buy Rating for CASI Pharmaceuticals: Here's What You Need To Know
November 15, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
November 03, 2023
Via
Benzinga
Why VOXX International Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
October 11, 2023
Gainers
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
October 11, 2023
Pre-market stock movers are a hot topic on Wednesday morning and we're covering all of the latest news investors need to know about!
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
September 27, 2023
Via
Benzinga
Week In Review: Mundipharma Considers $1 Billion Sale Of China Operations
August 05, 2023
Mundipharma is considering selling its China operations in a deal that could be worth $1 billion. Additionally, Oramed Pharma plans to form a $60 million JV with Hefei Tianhui Biotech to commercialize...
Via
Talk Markets
Week In Review: Novartis In $1 Billion Deal For DTx Pharma
July 22, 2023
Novartis signed a $1 billion agreement to acquire DTx Pharma, a preclinical San-Diego company developing siRNA therapies for neuroscience indications. Meanwhile, Zhuhai Biotheus formed a far-reaching...
Via
Talk Markets
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.